ClinicalTrials.gg
RecruitingNCT07242664Updated Nov 21, 2025

Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State

A Phase 1 interventional study of GZR-33 in Type 1 Diabetes Mellitis, sponsored by Gan and Lee Pharmaceuticals, USA. Recruiting at 2 sites in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Gan and Lee Pharmaceuticals, USA · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany — 22 open to participants now, 31 under way, 6 of them phase 3. Diabetes Mellitus, Type 1 · Germany.

Planned enrollment
245th of 260
12 · median 61
Started
2025
with 12 others
Phase 1
105 of 294
4 open now
Primary completion
2026-02
later than 1 of 30 live
Registered
285th of 294
by date
Lead sponsor
5 of 294
Gan and Lee Pharmaceuticals, USA

Among the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, this one is the 245th largest by planned enrollment of the 260 interventional ones that give a count, is one of 13 that started in 2025, is one of 105 in phase 1, reaches primary completion later than 1 of the 30 other live ones, and was the 285th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

22 of the 294 studies in Diabetes Mellitus, Type 1 with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 294 studies in Diabetes Mellitus, Type 1 with a site in Germany, or all of them as a file.
02

Study summary

This trial intends to investigate the pharmacodynamics, pharmacokinetics, safety, and tolerability of insulin GZR33 (hereafter referred to as GZR33) and estimate its potency in comparison with insulin degludec.

03

Conditions studied

  • Type 1 Diabetes Mellitis
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: type 1 diabetes for at least 12 months

  • 18-64 years of age
  • \<= 9.0%.
  • (BMI) between 18.5 and 29.0 kg/m\^2
  • treated with a stable insulin regimen for at least 2 months, in a dose > 0.2 and \< 1.2 U/kg/day

Exclusion Criteria:

  • blood pressure outside the range 90 to 140 mmHg (systolic) or 50 to 99 mmHg (diastolic)
  • concomitant diseases
  • recurrent severe hypoglycemia (more than 1 severe hypoglycemic episode requiring assistance from another person within 180 days before screening)
  • hypoglycemia unawareness
  • estimated (eGFR) \<60.0 mL/min/1.73 m2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Period 1 - GZR-33, period 2 insulin degludec

    Period 1 - GZR-33 once daily for six days. Post wash-out, insulin degludec once daily for six days

    Drug: GZR-33

  • Experimental
    Period 1 - insulin degludec, period 2 - GZR-33

    Period 1 - insulin degludec once daily for six days. Post wash-out, GZR-33 once daily for six days

    Drug: GZR-33

Interventions

  • DrugGZR-33

    GZR33 is a long-acting basal insulin analogue

06

What researchers measure

Primary outcomes

  1. the relative potency of GZR33 to insulin degludec

    Primary endpoint will be the relative potency of GZR33 to insulin degludec, according to the following equation: Relative Potency = GIR24h,ss,GZR33 /GIR24h,ss,degludec) × (Dosedegludec/DoseGZR33).

    Time frame: a two week run-in phase

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2026, 4 months after the start.

Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 4 months is below that.

Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Oct 13, 2025
Primary completionEst.
Feb 28, 2026
CompletionEst.
Apr 15, 2026
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07242664
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Oct 13, 2025
Primary completion
Feb 28, 2026 (estimated)
Completion
Apr 15, 2026 (estimated)
Last update
Nov 21, 2025

Study contacts

Andre Feldmann
Contact
149-1226-GZR-33@profil.com
+49 (0) 2131 4018 409

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GZR33

Start the discussion